



ASX / MEDIA RELEASE

21st April 2015

SIRFLOX Study Data Selected for an Oral Presentation at ASCO

Sydney, Australia; 21st April 2015 – Sirtex Medical Limited (ASX:SRX) (Sirtex) is delighted to announce that the American Society of Clinical Oncology (ASCO) Scientific Program Committee has selected the SIRFLOX study data for an Oral Abstract presentation (Abstract #3502) in the gastrointestinal (colorectal) cancer session at the ASCO Annual Meeting to be held from 3:00 p.m. to 6:00 p.m. (US Central Daylight Time) on Saturday, 30th May 2015. A total of only nine colorectal cancer abstracts were selected for this session.

Associate Professor Peter Gibbs, global principal investigator of the SIRFLOX study and Consultant Medical Oncologist, The Royal Melbourne Hospital, will present the findings of the SIRFLOX study at the meeting. The oral presentation is entitled “SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC).”

According to ASCO¹, the oral abstract session includes several 12-minute presentations of abstracts representing important clinical and translational research findings by topic category. Experts in the field (discussants) are chosen to provide comprehensive 12-minute themed discussions of the findings from predetermined abstracts. All speakers will participate in a question-and-answer panel in the session. For more information on the Oral Abstract Session format, please visit <http://am.asco.org/selection-process>.

Mr Gilman Wong, CEO of Sirtex commented “We are honoured the Scientific Program Committee has selected the SIRFLOX study for the Oral Abstract Session, which will allow the critical review of the study data as part of the overall peer review and validation process at the ASCO Annual Meeting, in front of such a large clinical audience.”

Until the peer review and validation process has been completed at the ASCO Meeting, Sirtex is unable to assess the commercial impact of the SIRFLOX study results.

For more information on the ASCO submission and session statistics, please visit <http://am.asco.org/abstract-submission-and-session-statistics>.

About ASCO

The ASCO Annual Meeting brings together 30,000 oncology professionals from around the world. Educational sessions feature world-renowned faculty discussing state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. Science sessions present the latest ground-breaking research in oral and poster format.

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406

About SIRFLOX

The SIRFLOX study is an international, multi-centre, randomised controlled study that enrolled over 500 patients with mCRC whose disease was non-resectable and had spread to either the liver alone or the liver plus a limited number of sites outside the liver, including lymph nodes and the lungs. The study was conducted in more than 100 hospitals across Australia, Europe, Israel, New Zealand and the United States. SIRFLOX is the first, large randomised controlled study that has examined the use of Selective Internal Radiation Therapy (SIRT, also known as radioembolisation) in the treatment of colorectal liver metastases. For more information, please visit www.sirflox.com and the ASX announcement made by Sirtex on 9th October 2014.

About SIR-Spheres[®] Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology to deliver Selective Internal Radiation Therapy or SIRT (also known as radioembolisation), a proven technology for inoperable liver tumours that delivers substantial, targeted doses of radiation directly to the cancer. Key SIR-Spheres Y-90 resin microspheres regulatory approvals include Pre-Market Approval (PMA) from the US FDA, European Union (CE Mark) approval and Australian TGA approval.

About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres[®] Y-90 resin microspheres. Approximately 50,000 doses have been supplied to treat patients with liver cancer at more than 800 medical centres in over 40 countries. For more information please visit www.sirtex.com.

For further information please contact:

Investor Enquiries:

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

Media Enquiries:

Tim Allerton or Andrew Geddes
City PR
Phone: +61 (0) 2 9267 4511

¹ <http://am.asco.org/selection-process>

SIR-Spheres[®] is a registered trademark of Sirtex SIR-Spheres Pty Ltd.